Rhythm is a biopharmaceutical company developing peptide therapeutics for the treatment of gastrointestinal (GI) diseases and obesity, including obesity caused by genetic deficiencies in the MC4 pathway. Our lead product candidate, relamorelin, is a potent, best-in-class, Phase 2 ghrelin agonist for the treatment of diabetic gastroparesis, a GI complication of diabetes, and other GI functional disorders. We are also developing a second product candidate, setmelanotide, which is a potent, first-in-class melanocortin-4 (MC4) receptor agonist for the treatment of obesity and obesity caused by genetic deficiencies in the MC4 pathway. We believe our product candidates, which are both administered by subcutaneous injection, and for which we have exclusive worldwide rights, have the potential to treat these diseases for which there are currently limited therapeutic options. We believe that ghrelin and MC4 are compelling targets because of their critical role in regulating GI function and metabolism, and that peptide therapeutics are well suited for activating these targets.
